First-in-human study of anticancer immunotherapy drug candidate mobilan: safety, pharmacokinetics and pharmacodynamics in prostate cancer patients

Toll-like receptor 5 (TLR5) controls endogenous immune responses to pathogens and is a promising target for pharmacological stimulation of anti-tumor immunity. Mobilan is an innovative gene therapy agent consisting of a non-replicating bicistronic adenovirus directing constitutive expression of huma...

Descripción completa

Detalles Bibliográficos
Autores principales: Eremina, Natalia V., Kazey, Vasily I., Mishugin, Sergey V., Leonenkov, Roman V., Pushkar, Dmitry Y., Mett, Vadim L., Gudkov, Andrei V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147088/
https://www.ncbi.nlm.nih.gov/pubmed/32292576
http://dx.doi.org/10.18632/oncotarget.27549

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147088/
https://www.ncbi.nlm.nih.gov/pubmed/32292576
http://dx.doi.org/10.18632/oncotarget.27549

Ejemplares similares